Literature DB >> 18641024

Effect of JAK2 V617F on thrombotic risk in patients with essential thrombocythemia: measuring the uncertain.

Panayiotis D Ziakas.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18641024     DOI： 10.3324/haematol.12970

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  21 in total

Review 1.  Management of myeloproliferative neoplasms: from academic guidelines to clinical practice.

Authors:  Giovanni Barosi; Letizia Lupo; Vittorio Rosti
Journal:  Curr Hematol Malig Rep       Date:  2012-03       Impact factor: 3.952

2.  Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor?

Authors:  Tiziano Barbui; Alessandra Carobbio; Alessandro Rambaldi; Guido Finazzi
Journal:  Blood       Date:  2009-04-16       Impact factor: 22.113

3.  Clinical relevance of JAK2 (V617F) mutant allele burden.

Authors:  Francesco Passamonti; Elisa Rumi
Journal:  Haematologica       Date:  2009-01       Impact factor: 9.941

Review 4.  Thrombosis in Philadelphia negative classical myeloproliferative neoplasms: a narrative review on epidemiology, risk assessment, and pathophysiologic mechanisms.

Authors:  Somedeb Ball; Kyaw Zin Thein; Abhishek Maiti; Kenneth Nugent
Journal:  J Thromb Thrombolysis       Date:  2018-05       Impact factor: 2.300

5.  Hemostatic disorders in a JAK2V617F-driven mouse model of myeloproliferative neoplasm.

Authors:  Lamia Lamrani; Catherine Lacout; Véronique Ollivier; Cécile V Denis; Elizabeth Gardiner; Benoit Ho Tin Noe; William Vainchenker; Jean-Luc Villeval; Martine Jandrot-Perrus
Journal:  Blood       Date:  2014-06-20       Impact factor: 22.113

6.  The impact of JAK2V617F mutation on different types of thrombosis risk in patients with essential thrombocythemia: a meta-analysis.

Authors:  Youwen Qin; Xiaorui Wang; Chuxian Zhao; Chun Wang; Yining Yang
Journal:  Int J Hematol       Date:  2015-05-22       Impact factor: 2.490

Review 7.  Risk Factors for and Management of MPN-Associated Bleeding and Thrombosis.

Authors:  Karlyn Martin
Journal:  Curr Hematol Malig Rep       Date:  2017-10       Impact factor: 3.952

Review 8.  JAK2 mutation and thrombosis in the myeloproliferative neoplasms.

Authors:  Alessandro M Vannucchi
Journal:  Curr Hematol Malig Rep       Date:  2010-01       Impact factor: 3.952

Review 9.  Assessing the thrombotic risk of patients with essential thrombocythemia in the genomic era.

Authors:  L Falchi; H M Kantarjian; S Verstovsek
Journal:  Leukemia       Date:  2017-05-22       Impact factor: 11.528

Review 10.  Insights into the pathogenesis and management of thrombosis in polycythemia vera and essential thrombocythemia.

Authors:  Alessandro M Vannucchi
Journal:  Intern Emerg Med       Date:  2009-09-30       Impact factor: 3.397
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.